Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:


TriPoint Global Research publishes Research Report on IGI, Laboratories, Inc. by Senior Analysts Richard W West, CFA and Sherry Grisewood, CFA
  • Industry: Pharmaceuticals & Biotechnology
  • Current Rating: Market Perform
  • Rating Assigned: 6/13/2011
  • Analyst: Richard W West, CFA and Sherry Grisewood, CFA

A 23-page Research Report is available for download at, as well as other leading financial portals, that include Reuters, Capital IQ and Research Direct on Bloomberg terminals by entering TRPN.

About IGI, Laboratories, Inc. (Amex - IG)

IGI, Laboratories, Inc. is a topical pharmaceuticals and OTC products manufacturer primarily engaged in the production and packaging of formulations and agents used in pharmaceuticals, cosmetics, and consumer skin care products. IGI’s expertise lies in the development, formulation, turnkey manufacturing, filling and packaging of topical semi-solid, suspension and liquid products, many of which incorporate novel encapsulation and delivery technologies.

About TriPoint Global Research, LLC:

TriPoint Global Research, LLC is an independent investment research firm. Its senior analysts are primarily CFAs, and have expertise in many industries. A TriPoint Global Research, LLC research report or note is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed. Neither the firm, its principals nor the assigned analysts own or trade shares of any company covered. The firm does not accept any equity compensation. TriPoint Global Research, LLC received $17,000 from an individual investor for one research report.

Copyright Business Wire 2010

If you liked this article you might like

Strong On High Volume: IGI Laboratories (IG)

Today's Weak On High Volume Stock: IGI Laboratories (IG)

Trade-Ideas: IGI Laboratories (IG) Is Today's Strong On High Relative Volume Stock

5 Stocks Set to Soar on Bullish Earnings

5 Biotech Stocks Poised for Breakouts